Academic Journal
Urease inhibitors: current advances, therapeutic potentials, and clinical challenges.
| Τίτλος: | Urease inhibitors: current advances, therapeutic potentials, and clinical challenges. |
|---|---|
| Συγγραφείς: | Alzoubi OH; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Khamees A; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan.; Princess Basma Teaching Hospital, Ministry of Health, Irbid, Jordan., Alzu'bi MB; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Freihat SF; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Attar A; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Abo Sameed H; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Alzubi R; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Alsamarah AA; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Yassin RY; Faculty of Pharmacy, Yarmouk University, Irbid, Jordan., Al-Shami K; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan., Al-Trad B; Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia., Al-Zoubi RM; Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.; Department of Chemistry, Jordan University of Science and Technology, Irbid, Jordan.; Department of Biomedical Sciences, QU-Health, College of Health Sciences, Qatar University, Doha, Qatar., Al Zoubi MS; Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan. |
| Πηγή: | Future medicinal chemistry [Future Med Chem] 2026 Jul; Vol. 18 (14), pp. 1907-1923. Date of Electronic Publication: 2026 Jun 15. |
| Τύπος έκδοσης: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101511162 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-8927 (Electronic) Linking ISSN: 17568919 NLM ISO Abbreviation: Future Med Chem Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2024- : [Milton Park, Oxfordshire] : Taylor & Francis Original Publication: London : Future Science, 2009- |
| Ιατρικοί όροι (MeSH): | Urease*/antagonists & inhibitors , Urease*/metabolism , Enzyme Inhibitors*/chemistry , Enzyme Inhibitors*/pharmacology , Enzyme Inhibitors*/therapeutic use, Helicobacter pylori/drug effects ; Helicobacter pylori/enzymology ; Helicobacter Infections/drug therapy ; Humans ; Animals |
| Περίληψη: | Urease is a nickel-dependent metalloenzyme that catalyzes urea hydrolysis, generating ammonia and elevating local pH, a process implicated in the pathogenesis of Helicobacter pylori-associated peptic ulcer disease (PUD). To identify effective urease inhibitors, acetohydroxamic acid (AHA) remains the only FDA-approved agent, with clinical use constrained by toxicity. This review synthesizes current evidence on urease inhibition strategies, encompassing metal-based complexes, organic derivatives, natural products, peptide inhibitors, nanotechnology-enabled systems, and emerging gene-based approaches. Several candidates, including copper-based compounds and the natural alkaloid palmatine (PAL), demonstrate potent urease inhibition and favorable effects in preclinical models. However, translation to clinical practice is limited by safety concerns, instability, and a paucity of human trials. Advancing hybrid molecules, optimized delivery platforms, and combination therapies may enhance therapeutic efficacy. Rigorous clinical evaluation remains essential to establish urease inhibition as a viable strategy in urease-mediated diseases. |
| References: | Antibiotics (Basel). 2021 Dec 08;10(12):. (PMID: 34943720) Chem Rev. 2014 Jan 8;114(1):815-62. (PMID: 24102434) J Enzyme Inhib Med Chem. 2023 Dec;38(1):2220084. (PMID: 37318308) Pharmaceutics. 2022 Jul 14;14(7):. (PMID: 35890358) J Enzyme Inhib Med Chem. 2006 Aug;21(4):467-70. (PMID: 17059182) Lancet. 1990 Jan 27;335(8683):193-5. (PMID: 1967668) Bioorg Chem. 2024 Nov;152:107735. (PMID: 39213798) Nat Commun. 2024 Mar 12;15(1):2226. (PMID: 38472276) Med Clin North Am. 2023 May;107(3):517-531. (PMID: 37001951) Pharmacol Rep. 2021 Jun;73(3):891-906. (PMID: 33389728) Curr Med Chem. 2002 Jul;9(14):1323-48. (PMID: 12132990) Q J Nucl Med Mol Imaging. 2008 Sep;52(3):267-77. (PMID: 18475250) Mar Drugs. 2020 Oct 29;18(11):. (PMID: 33138146) Bioorg Chem. 2021 Apr;109:104691. (PMID: 33601138) J Adv Res. 2018 Mar 26;13:113-126. (PMID: 30094086) Dig Dis Sci. 1998 Jan;43(1):109-19. (PMID: 9508511) Planta Med. 2005 Mar;71(3):197-201. (PMID: 15770537) Med Clin North Am. 1991 Jul;75(4):799-814. (PMID: 2072787) Phytother Res. 2015 Jan;29(1):67-72. (PMID: 25243578) Int J Antimicrob Agents. 2002 Jun;19(6):488-98. (PMID: 12135839) J Nanobiotechnology. 2022 Jun 7;20(1):262. (PMID: 35672712) Molecules. 2016 Nov 26;21(12):. (PMID: 27898047) PLoS One. 2023 Jun 2;18(6):e0286684. (PMID: 37267378) Digestion. 2006;73 Suppl 1:86-93. (PMID: 16498256) Nephron. 1999;81 Suppl 1:50-9. (PMID: 9873215) Helicobacter. 2017 Sep;22 Suppl 1:. (PMID: 28891130) Biophys Rev. 2021 Mar 29;13(2):259-272. (PMID: 33936318) EcoSal Plus. 2018 Feb;8(1):. (PMID: 29424333) J Endourol. 2023 Mar;37(3):358-366. (PMID: 36562270) Nat Rev Urol. 2014 Jun;11(6):333-41. (PMID: 24818849) Expert Opin Ther Pat. 2011 Jun;21(6):945-57. (PMID: 21457123) Gut Liver. 2015 Jul;9(4):486-93. (PMID: 25287166) Bioorg Med Chem. 2018 Jul 30;26(13):3791-3804. (PMID: 29903414) J Adv Res. 2018 May 04;13:69-100. (PMID: 30094084) J Urol. 1978 Jan;119(1):9-15. (PMID: 23442) RSC Adv. 2023 Jan 23;13(5):3210-3233. (PMID: 36756398) Urol Clin North Am. 2015 Nov;42(4):459-72. (PMID: 26475943) Invest Urol. 1978 May;15(6):498-501. (PMID: 649302) Molecules. 2021 May 01;26(9):. (PMID: 34062878) Subcell Biochem. 2014;73:7-29. (PMID: 25298336) World J Gastroenterol. 2010 Nov 28;16(44):5629-34. (PMID: 21105198) Eur Urol. 1991;20(3):243-7. (PMID: 1726639) Curr Protein Pept Sci. 2012 Dec;13(8):789-806. (PMID: 23305365) Int J Biol Macromol. 2024 Sep;276(Pt 1):133735. (PMID: 38986980) Clin Liver Dis. 2024 May;28(2):253-263. (PMID: 38548437) J Clin Pathol. 2010 May;63(5):424-30. (PMID: 20418234) J Enzyme Inhib Med Chem. 2023 Dec;38(1):361-375. (PMID: 36446640) Biochem Biophys Res Commun. 2001 Jul 20;285(3):728-33. (PMID: 11453654) Sci Rep. 2024 Jan 10;14(1):943. (PMID: 38200115) J Clin Pathol. 1991 Aug;44(8):695-7. (PMID: 1890207) Bioorg Chem. 2019 Mar;83:595-610. (PMID: 30513472) J Adv Res. 2015 Jan;6(1):35-44. (PMID: 25685542) Scand J Gastroenterol Suppl. 1991;187:39-46. (PMID: 1775923) PLoS One. 2017 Jan 3;12(1):e0168944. (PMID: 28045966) J Ethnopharmacol. 2022 Sep 15;295:115388. (PMID: 35577159) Future Med Chem. 2024;16(20):2151-2168. (PMID: 39297549) Mini Rev Med Chem. 2020;20(7):532-565. (PMID: 31755386) Curr Top Med Chem. 2022;22(2):95-107. (PMID: 34844543) Infect Immun. 1987 Aug;55(8):1751-4. (PMID: 3112009) Eur J Med Chem. 2014 Mar 3;74:314-23. (PMID: 24486414) Microorganisms. 2024 Sep 30;12(10):. (PMID: 39458296) Ann Hepatol. 2003 Jul-Sep;2(3):122-30. (PMID: 15115963) J Agric Food Chem. 2008 Sep 24;56(18):8451-60. (PMID: 18729463) Urology. 1975 Mar;05(3):299-302. (PMID: 1118989) BMC Microbiol. 2023 Dec 19;23(1):401. (PMID: 38114907) Biometals. 2006 Oct;19(5):503-11. (PMID: 16937256) Sci Rep. 2020 May 22;10(1):8503. (PMID: 32444844) Front Pharmacol. 2021 Nov 03;12:762807. (PMID: 34803707) Prim Care. 2020 Dec;47(4):661-671. (PMID: 33121635) J Clin Pathol. 1993 Apr;46(4):372-3. (PMID: 8496397) J Adv Res. 2018 Jan 31;13:101-112. (PMID: 30094085) Bioorg Chem. 2019 Aug;89:103024. (PMID: 31176853) Nat Rev Dis Primers. 2016 Feb 25;2:16008. (PMID: 27188687) JAMA. 2024 Dec 3;332(21):1832-1842. (PMID: 39466269) ChemMedChem. 2022 Jan 19;17(2):e202100618. (PMID: 34687265) Iran J Basic Med Sci. 2019 Oct;22(10):1118-1124. (PMID: 31998451) Molecules. 2017 Aug 16;22(8):. (PMID: 28813027) J Adv Res. 2018 Jan 31;13:51-57. (PMID: 30094082) Aliment Pharmacol Ther. 2004 Nov 15;20(10):1001-17. (PMID: 15569102) Cells. 2020 Dec 25;10(1):. (PMID: 33375694) Front Chem. 2024 Mar 13;12:1371377. (PMID: 38545466) Eur J Clin Pharmacol. 1985;28(4):439-45. (PMID: 3928387) Eur J Biochem. 1999 Jun;262(3):774-80. (PMID: 10411639) Aliment Pharmacol Ther. 1996 Apr;10 Suppl 1:57-64. (PMID: 8730260) J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S29-36. (PMID: 26041954) Infect Immun. 1997 Apr;65(4):1181-8. (PMID: 9119449) PLoS Pathog. 2017 Jun 23;13(6):e1006464. (PMID: 28644872) PLoS Biol. 2018 Jan 10;16(1):e2003887. (PMID: 29320492) Environ Geochem Health. 2021 May;43(5):2037-2048. (PMID: 33244649) Front Microbiol. 2024 Nov 15;15:1464484. (PMID: 39619692) Children (Basel). 2017 Jan 04;4(1):. (PMID: 28054971) Int J Mol Med. 2021 Aug;48(2):. (PMID: 34132361) |
| Contributed Indexing: | Keywords: Helicobacter pylori; Urease inhibitors; acetohydroxamic acid; hepatic encephalopathy; struvite kidney stones |
| Substance Nomenclature: | EC 3.5.1.5 (Urease) 0 (Enzyme Inhibitors) |
| Entry Date(s): | Date Created: 20260615 Date Completed: 20260703 Latest Revision: 20260911 |
| Update Code: | 20260911 |
| PubMed Central ID: | PMC13557569 |
| DOI: | 10.1080/17568919.2026.2684497 |
| PMID: | 42290516 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!